A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis bullosa associated Locally Advanced/Metastatic Squamous Cell Carcinoma
This research study is looking into a new medicine called Rigosertib for people aged 18 and over who have a type of skin cancer called squamous cell carcinoma. This cancer is specifically linked to a rare skin condition called Recessive Dystrophic Epidermolysis Bullosa (RDEB), where the skin is very fragile. The cancer in this study has either spread nearby or to other parts of the body. The main goal of the study is to see if Rigosertib can make the cancer shrink or stop growing. The researchers also want to find out if the medicine is safe and easy for people to take. They will be giving Rigosertib either as capsules to swallow or through a drip into a vein.
A colpo d'occhio
Di cosa tratta questo studio?
This study is a Phase II clinical trial, which means it's one of the earlier stages of testing a new medicine in people. The medicine being tested is called Rigosertib, and it's for adults who have a specific, more advanced type of skin cancer. This skin cancer, called squamous cell carcinoma, is related to a very rare and serious genetic skin condition called Recessive Dystrophic Epidermolysis Bullosa, often shortened to RDEB. People with RDEB have extremely fragile skin that blisters and scars easily, and unfortunately, they have a higher risk of developing this type of skin cancer.
The main purpose of this study is to see how well Rigosertib works against this specific type of cancer. Doctors want to know if it can cause the cancer to shrink or stop it from growing. They will be carefully measuring the size of the cancer over a period of time, up to about a year, using scans like CT or MRI. They also want to understand if the medicine is safe to use and what side effects people might experience.
Participants will receive Rigosertib either as capsules they take by mouth, or through a drip into a vein. The schedule for taking the medicine will vary depending on whether it's taken by mouth or through a drip. The study will also look at how the medicine affects a person's quality of life and will examine tissue samples to understand more about how the medicine works at a cellular level.
Punti chiave
- This study tests a new medicine, Rigosertib, for a type of skin cancer linked to RDEB.
- It aims to see if the medicine can shrink the cancer and if it's safe to use.
- Rigosertib can be given as capsules or through a drip.
- The study lasts up to a year with regular check-ups and scans.
- Your quality of life will also be monitored throughout the study.
Chi può essere idoneo?
To be part of this study, you need to be an adult, aged 18 or older.
You must have a specific type of skin cancer, called squamous cell carcinoma, which is linked to having Recessive Dystrophic Epidermolysis Bullosa (RDEB). This cancer needs to be locally advanced (meaning it has grown into nearby tissues) or metastatic (meaning it has spread to other parts of your body).
There will be other detailed medical checks to make sure the treatment is safe for you and that you will benefit most from participating. These checks will be explained fully by the study team.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai 18 anni o più?
- Do you have squamous cell carcinoma of the skin related to RDEB?
- Has your cancer spread locally or to other parts of your body?
- Are you able to travel to the study site for regular appointments?
- Are you generally well enough to take part in a clinical trial?
Cosa comporta la partecipazione?
If you join this study, you'll be given the medicine Rigosertib. This can be either as capsules you swallow (or dissolved in liquid), or through a drip into your arm (intravenous, or IV). If you take capsules, you'll take them daily for three weeks, then have one week off, and this cycle will repeat. If you receive it through a drip, it will be a continuous slow infusion for 72 hours (3 days) at the start of a two-week cycle for a few months, and then on the first three days of a four-week cycle afterwards.
You will have regular check-ups, scans (like CT or MRI) to see how the cancer is responding, and blood tests. Doctors will also ask you about your general well-being and how you're feeling, including your quality of life. The study will last for up to 52 weeks (about a year) where your cancer will be regularly assessed. After this, you will still be monitored for safety.
Rischi e benefici potenziali
Luoghi (1)
- —Non verificatoAustria
Domande comuni
What is Rigosertib?
Rigosertib is the new medicine being tested in this study. It's designed to target certain pathways that help cancer cells grow.
What does 'Phase II' mean?
Phase II means this is an early stage of testing where doctors are looking to see if the medicine works and is safe in a small group of people with the specific condition.
What is Recessive Dystrophic Epidermolysis Bullosa (RDEB)?
RDEB is a rare genetic skin condition that makes the skin very fragile, prone to blistering and scarring. People with RDEB have a higher risk of developing certain skin cancers.
How will doctors know if the medicine is working?
Doctors will use scans like CT or MRI to measure the size of your cancer over time and see if it is shrinking or stable.
Dovrò pagare per partecipare allo studio?
No, you will not have to pay for the study medicine or study-related tests and appointments. However, you should discuss any potential travel costs or other expenses with the study team.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.